We wouldn't blame Halozyme Therapeutics, Inc. (NASDAQ:HALO) shareholders if they were a little worried about the fact that Matthew Posard, the Independent Director recently netted about US$1.0m selling shares at an average price of US$50.32. That's a big disposal, and it decreased their holding size by 20%, which is notable but not too bad.

Halozyme Therapeutics Insider Transactions Over The Last Year

Notably, that recent sale by Matthew Posard is the biggest insider sale of Halozyme Therapeutics shares that we've seen in the last year. So we know that an insider sold shares at around the present share price of US$49.50. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern.

Halozyme Therapeutics insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.

Insider Ownership Of Halozyme Therapeutics

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. It appears that Halozyme Therapeutics insiders own 1.0% of the company, worth about US$66m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

So What Do The Halozyme Therapeutics Insider Transactions Indicate?

An insider hasn't bought Halozyme Therapeutics stock in the last three months, but there was some selling. And there weren't any purchases to give us comfort, over the last year. But it is good to see that Halozyme Therapeutics is growing earnings. Insiders own shares, but we're still pretty cautious, given the history of sales. We're in no rush to buy! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Halozyme Therapeutics. For example - Halozyme Therapeutics has 2 warning signs we think you should be aware of.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com